TGI and Viracor Announce Transplant Advisory Board, to focus on trends and innovations in transplant diagnostics
Viracor and Transplant Genomics Inc (TGI) announce the formation of the Eurofins Transplant Medical and Scientific Advisory Board, employing diverse expertise and experience in transplantation and technology development to enhance the clinical value of diagnostics throughout the transplant community.
Lab Economics - May: COVID-19 Situation Updates
New York Times - These Labs Rushed to Test for Coronavirus. They Had Few Takers
The fragmented U.S. health care system has hampered efforts to expand coronavirus testing, by making it difficult for hospitals to switch to new labs with ample capacity.
KCTV5 News - Lab in Lee's Summit validates COVID-19 antibody test
Antibody testing is a sign that you’ve had the virus in the past,” says Dr. Michelle Altrich. “In order to understand really the number of people that have had the virus, we can now use antibody testing to give us an idea of what that prevalence really looks like.”
Fox 4 News - Lee's Summit Lab Begins Antibody Testing
Determining how many people may have been exposed to the coronavirus and don't realize it is one of the goals behind antibody testing, which Viracor Eurofins in Lee's Summit started this week.
KSHB 41 News - Lee's Summit lab now offers COVID-19 antibody testing, Interview with Dr. Michelle Altrich
"Since we know that early on in the pandemic, we didn’t have enough testing to go around, there’s no way to know how many people have actually had the virus unless we go back and look for a sign that they had it two months ago or three months ago," Michelle Altrich, the company's president, said. "That is what antibody testing can do for us. It can give us an idea of what really is the prevalence of the infection and that will help managing the pandemic at a very large scale."
Viracor Launches Highly Accurate Antibody Tests for Coronavirus COVID-19 SARS-CoV-2
The serology testing, developed in accordance with the FDA’s Emergency Use Notification process, was 100% accurate in finding antibodies in COVID-19 positive patient samples (12 days post symptom onset). Using a wider sample group from PCR positive patients, the IgG test showed a specificity of 99.1% (9 days post symptom onset. The tests can detect IgM antibodies (typically present approximately 2-5 days post-infection) and IgG antibodies (typically present approximately 2-4 weeks post-infection). Viracor has the capacity to result more than 2,000 tests per day with a 24 hour turnaround from specimen receipt.
Laboratory Economics - April: COVID-19 Spotlight Interview with Dr. Steve Kleiboeker
BioKansas - Viracor Looks to Partner with Kansas City Community on COVID-19 Testing
Viracor Eurofins has been at the forefront of fighting SARS-CoV-2 in the US, having launched testing on March 13 using polymerase chain reaction (PCR) with same or next day results for PCR, and 2-4 days for blood-based antibody testing. The laboratory’s current focus is reaching out to our local communities in Kansas and Missouri that may be in need of testing.
Fox Business ‘After the Bell’ talks with David Morgan, SVP of Eurofins U.S. Clinical Diagnostics
Fox Business discusses Eurofins' launch of coronavirus antibody testing with David Morgan, Senior Vice President of U.S. Clinical Diagnostics
Viracor Partners with VA New England Veterans Healthcare System to Offer COVID-19 Testing
Viracor will offer two types of COVID-19 tests through the company’s established contract with the GSA (U.S. General Services Administration Contract):
- NP swab-based PCR tests to determine active infection
- Blood-based antibody testing. This may become a tool to identify people who were exposed to COVID-19, may have developed some level of immunity but potentially had mild to no symptoms.
CommonWealth - If you survive COVID-19, are you immune?
The FDA is also allowing commercial labs to run these types of tests without FDA review. Framingham-based Boston Heart Diagnostics started offering a blood test on Monday that measures COVID-19 antibodies. The test is not meant to diagnose the virus, but it can be used to determine if someone had COVID-19 in the past and whether the virus is still present.
Viracor Eurofins Receives Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 RT-PCR laboratory-developed test (LDT)
Viracor Eurofins, one of the largest and most recognised infectious diseases testing laboratories in the U.S., was granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Clinical Diagnostics' molecular laboratory-developed test (LDT). The Viracor SARS-CoV-2 assay is a real-time polymerase chain reaction (RT-PCR) test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab and bronchoalveolar lavage from individuals suspected of COVID-19. The Viracor EUA is available on https://www.fda.gov/media/136740/download.
The National Kidney Registry and Viracor Eurofins Announce Coronavirus Antibody Testing for Donors and Recipients
“We are pleased to announce that COVID-19 antibody testing will be available to NKR Member Centers by Friday, April 10th. Some centers are already planning to use the newly released antibody test for screening donors and recipients prior to surgery, in conjunction with the PCR test, and for research related to waitlisted patients and transplant recipients.” Said Garet Hil, Founder and CEO, National Kidney Registry. “We are grateful for the rapid response from Eurofins in developing this solution and we indebted to key members of our Medical Board for guiding us through this process.
NBC Boston - Eurofins' Boston Heart Diagnostics Develops Antibody Test for Coronavirus
Boston Heart's Patrick Noland discusses blood-based antibody testing for COVID-19
The Doctor's Farmacy - Dr. Hyman Podcast: What You Need to Know About COVID-19 Testing with Dr. Steve Kleiboeker
Viracor's Dr. Steve Kleiboeker talks with Dr. Hyman on the The Doctor's Farmacy about who should be tested for COVID-19, when, and how, and what kinds of tests are currently available or soon will be. In addition, they discuss some of the most confusing COVID-19 recommendations, like if the general public should wear masks as a protective measure.
NPR Boston - Eurofins' Boston Heart Diagnostics Lab Launches Rapid Test for Telltale Coronavirus Antibodies
The COVID-19 blood-based serology test looks for a type of antibodies that reflect having had active disease, and it's thought the best time to test for them is at 14 days after infection. The lab hopes to participate in research with local hospitals to monitor patients' immune response over time and possibly to help with efforts to develop treatments from antibodies.
FierceBiotech - Eurofins lays out plans for high-throughput COVID-19 antibody blood testing
Global testing company Eurofins announced it will begin offering large-scale, blood-based COVID-19 antibody testing in Massachusetts through its Viracor and Boston Heart Diagnostics subsidiaries.
Starting April 6, hospitals on the East Coast will be able to ship blood samples to Boston for analysis, according to Eurofins, which expects to start processing 200 tests per hour, or about 4,800 per day. Additionally, Viracor said it plans to offer its own test in mid-April.
Boston Herald - Eurofins' Massachusetts lab launches coronavirus antibody test
Eurofins U.S. Clinical Diagnostics Network's Boston Heart Diagnostics has launched a coronavirus COVID-19 antibody blood-based test for area hospitals—where the need is the highest ahead of an anticipated surge in the coming weeks. The serology lab test may be able to identify if a person is immune to the highly contagious disease and could be the key in fighting the spread of the virus.
BioSpace - Update on the Novel Coronavirus
The Eurofins’ U.S. Clinical Diagnostics network has launched an Antibody Test for hospital workers, first responders and patients. Testing will occur at Boston Heart Diagnostics, a Eurofins subsidiary.
Eurofins’ U.S. Clinical Diagnostics Network Launches Coronavirus (COVID-19) Antibody Testing
The Eurofins’ U.S. Clinical Diagnostics network announced today that blood-based antibody testing for Coronavirus SARS-CoV-2 will begin Monday, April 6 at Boston Heart Diagnostics, a Eurofins subsidiary. Given the overwhelming demand in acute care settings, the laboratories will initially offer the test to hospitals only. As capacity increases, and as knowledge on the disease develops, the Eurofins’ network plans to begin offering testing more broadly
Viracor Eurofins Launches Labs@HOME, a Mobile Phlebotomy Service for Post-Transplant Patient Testing During COVID-19
Labs@HOME is a mobile phlebotomy, at-home blood draw service for immunocompromised patients who must limit interaction in the hospital during the COVID-19 outbreak. This service will aid in specimen collection for vital post-transplant testing, directly from a patient’s home.
CNN - Coronavirus Test Results Across the US
Viracor Eurofins said its labs are running up to 5,000 tests a day, many in 24 hours, but also said, “due to the backlog, unprecedented demand, pressures on our supply chain, and shipping delays … our turnaround time has been pushed beyond what we normally experience.
Eurofins Transplant Genomics and Viracor will Partner to Offer Remote Sample Collection Options to Support Care for Kidney Transplant Recipients During COVID-19 Outbreak
Transplant Genomics, Inc. today announced that it has partnered with sister Eurofins company Viracor, and established relationships with Quest and various mobile sample collection groups, to enable patients to have samples collected remotely for analysis with our unique catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.
U.S. News - Missouri Lab Develops Test for Coronavirus
KCUR reports that Viracor Eurofins in Lee's Summit claims it is capable of performing more than 1,000 tests per day and returning results the same day.
Officials say the test would allow for expanding testing to patients who don't currently meet the eligibility criteria for public laboratory testing established by the Centers for Disease Control and Prevention
USA Today - News from Around the U.S.
A clinical lab in the state says it has developed a test for the novel coronavirus that is more than 99% accurate. KCUR reports Viracor Eurofins in Lee’s Summit claims it is capable of performing more than 1,000 tests per day and returning results the same day.
The Kansas City Star - Coronavirus in Missouri and Kansas: Where an how to get tested, and what's changing
In the Kansas City area, three national private commercial labs — Quest Diagnostics, LabCorp and Lee’s Summit-based Viracor Eurofins — are now also processing tests. You cannot go there directly. Ask your doctor’s office if they use one of these labs and what criteria they use to decide who gets tested.
NPR KCUR 89.3 - Lab In Lee’s Summit Says It Has Developed A Rapid Test For The New Coronavirus
Viracor Eurofins, which was founded in 1983, says it's capable of performing more than 1,000 tests per day and returning results the same day. The test will allow clinicians to expand testing to patients who currently don't meet the eligibility criteria for public laboratory testing established by the Centers for Disease Control and Prevention.
The National Kidney Registry and Viracor Eurofins Announce Coronavirus COVID-19 Rapid Turnaround Transplant Testing for Donors and Recipients
The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership today to deliver testing for Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR's vast network of Member Centers.
KMBZ Radio Interview - What testing looks like for COVID-19
Interview with Dr. Steve Kleiboeker, Viracor Coronavirus COVID-19 SARS test
KSHB 41 News - Lee's Summit Lab Testing for Coronavirus to Help Combat Spread of Virus
Interview with Dr. Steve Kleiboeker
The company first became interested in developing a test for COVID-19 in December after watching what was happening in China. By the middle of January, Kleiboeker said his scientists believed they could help with the demand for test kits by developing their own in-house testing.
KMBC 9 News - Local Lab to Begin Testing for COVID-19 with Same Day Results
Interview with Dr. Steve Kleiboeker
A local lab has received the green light from the Food and Drug Administration to begin testing for COVID-19 and it is able to process a thousand samples a day.
"Knowing the cause of the illness is the very first step to the most effective care," said Steve Kleiboeker, of Viracor Eurofins.
Contract PHARMA - Eurofins Offers Coronavirus Testing Services
Global testing and laboratory services firm Eurofins, said two of its clinical diagnostic testing laboratories in the U.S. now offer testing for evaluation of COVID-19. On March 13, 2020, Viracor Eurofins, one of the largest infectious diseases testing laboratories in the U.S., is launching a stand-alone real time reverse transcriptase PCR assay for the qualitative detection of SARS-CoV-2.
KCTV 5 News - Local Lab May Soon Help Battle Coronavirus COVID-19
Interview with Dr. Michelle Altrich
Doctors across the country are frustrated with the restricted access to COVID-19 testing. The CDC has guidelines for which patients qualify. Those guidelines will not apply to commercial facilities like one in Lee’s Summit.
KC Business Journal - Lee's Summit Lab to Start Testing Coronavirus COVID-19
Lee's Summit-based clinical specialty lab soon will start testing samples for the novel coronavirus, COVID-19. Viracor Eurofins will begin testing March 13, in accordance with the Food and Drug Administration's Emergency Use Authorization Guidance, with results in 12 to 18 hours.
NTD Eurofins Offers Coronavirus SARS-CoV-2 Testing Through Viracor Eurofins
NTD Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will offer testing for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020 through its sister company Viracor Eurofins. The new test utilizes real-time reverse-transcriptase polymerase chain reaction (RT-PCR) technology to detect the new coronavirus (SARS-CoV-2). Viracor's qualitative Coronavirus SARS-CoV-2 RT-PCR assay will be tested on Nasal Swab specimens. Healthcare providers can expect results within 1-2 to days from receipt at NTD
Viracor Eurofins Launches Coronavirus (COVID-19) SARS-CoV-2 RT-PCR Test with Same Day Results (12-18 Hours)
Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus (COVID-19) SARS-CoV-2 Test RT-PCR as of March 13, 2020.
Eurofins Expands Kidney Transplant Diagnostics Offering Through Viracor TRAC™
Viracor announces a donor derived cell-free DNA (dd-cfDNA) assay, Viracor TRAC™, to complement its suite of testing that supports successful outcomes for patients with kidney transplants. Viracor TRAC™ Kidney is now available to order.
Viracor Eurofins Expands Its Clinical Diagnostic Footprint to Oncology
Dr. Karina Eterovic joins Viracor as the Director of Research & Development for Oncology Diagnostics for Eurofins U.S. Clinical Diagnostics group
MolDX Sets TruGraf Reimbursement Level
Transplant Genomics, Inc. receives notice that the Molecular Diagnostics Services (MolDX) Program developed by Palmetto GBA has set TruGraf reimbursement.
Transplant Genomics, Inc. Confirms TruGraf Will Receive Medicare Coverage Effective November 25, 2019
Transplant Genomics and Viracor's innovative TruGraf ® Blood Gene Expression Test qualifies for Medicare coverage effective November 25, 2019.
Eurofins Viracor, Inc. Responds to Patent Infringement Lawsuit By CareDx
Eurofins Viracor, Inc. (“Viracor”) became aware today that CareDx has filed suit in the United States District Court for District of Delaware, alleging infringement of U.S. Patent No. 8,703,652 by three of Viracor’s tests: Viracor TRAC™ Kidney dd-cfDNA, Viracor TRAC™ Heart dd-cfDNA and Viracor TRAC™ Lung dd-cfDNA.
Viracor Eurofins Collaborates with Northwestern University Comprehensive Transplant Center on Specialized Kidney Transplant Diagnostic
Viracor Eurofins announces research collaboration with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America through high impact research and its clinical training programs. This research collaboration will further verify the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”), and its blood gene expression test, TruGraf®.
Eurofins Expands its Transplantation Testing Footprint with the Acquisition of Transplant Genomics Inc.
Eurofins Scientific (EUFI.PA), announces that it has successfully closed the acquisition of Transplant Genomics Inc. (“TGI”), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. TGI’s innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants will strengthen and complement Eurofins’ industry leading global Transplant Diagnostics offerings.
Viracor Eurofins Launches Baloxavir marboxil (XOFLUZA™) Influenza A Antiviral Resistance PCR for 2019 Flu Season
Baloxavir Resistance Testing was developed for the detection of I38T/M/F mutations in H3N2 and 2009 H1N1 strains of Influenza A (flu A) to aid in the evaluation of resistance to the recent FDA approved drug.
16S Next Generation Sequencing Bacterial Meningitis test from Viracor Eurofins provides actionable results to improve patient outcomes
Healthcare professionals can detect and identify the most common bacterial pathogens
associated with meningitis, with results in 3 days
Viracor Eurofins offers first commercially available letermovir genotypic sequencing test to help healthcare professionals manage CMV
Innovative Options in CMV Testing Plus Industry-Leading Turnaround Time Helps Reduce the Risk for CMV Morbidity and Mortality
Viracor Eurofins Announces Medical Advisory Board
Industry-leading infectious disease and transplant physicians help Viracor ideate and innovate to serve unmet testing needs, improving patient care and outcomes
Viracor Eurofins' Algorithms Predict Risk of aGVHD and Non-relapse Mortality in Allogeneic HCT Patients
New algorithms with clinically validated cutoffs aid in treatment decisions and modifications prior to or early in the disease process, to improve patient outcomes
Eurofins Scientific Donates €1 Million to Mark its 30-Year Anniversary
Eurofins Scientific (EUFI.PA) marks its 30th anniversary by donating €1 million to 40 charities selected by its global workforce.
Viracor-IBT Laboratories, Inc.’s Zika Virus RT-PCR Test Receives Emergency Use Authorization From the FDA
Test Provides U.S. Physicians and Patients Same Day Results and the Option to Test Urine Alongside Blood
Viracor-IBT Partners with USA Today Transplant Coverage
Viracor-IBT is excited to partner with USA Today's Transplants: The Gift of Life, an annual supplement bringing attention to transplantation and the organ donation industries united work to raise awareness about gifting one's organs in order to help save the lives of others.
Published scientific study proves efficacy of ImmuKnow® test, improving patient survival rate
The study demonstrated that the ImmuKnow assay provided additional data which helped optimize immunosuppression, and ultimately improve patient survival rate3.
The National Kidney Registry Partners with Viracor-IBT Laboratories to Accelerate Living Donor Transplantation
The National Kidney Registry (NKR) and Viracor-IBT Laboratories announced today a partnership to streamline pre-transplant serology testing for kidney donors.
Eurofins signs agreement to acquire Viracor-IBT Laboratories, Inc.
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, has signed a definitive agreement to acquire ViraCor-IBT Laboratories, Inc. (VIBT) from majority owner Ampersand Capital and other shareholders for approximately $255m, subject to post-closing adjustments.
Viracor-IBT Laboratories' Acquisition of the National Institute of Transplantation Enhances Testing Services for Transplant Patients.
Viracor-IBT Laboratories, Inc. announced today it has closed on its previously announced transaction to purchase assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation. NIT made the decision to transfer its laboratory operations to Viracor-IBT to perpetuate the mission of its foundation, build on the legacy of its laboratory operations, and to provide testing services to more transplant patients across the U.S.
Viracor-IBT Laboratories Acquires Assets of the National Institute of Transplantation
Viracor-IBT Laboratories, Inc. announced today it has signed a definitive agreement to purchase all assets associated with the laboratory operations of the National Institute of Transplantation (NIT), a non-profit organization committed to advancing the science and practice of transplantation.
Viracor-IBT Laboratories Acquires Assets of Cylex™
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of CylexTM, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Viracor-IBT Laboratories Launches the First Assay to Identify a New Type of Delayed, IgE-based Allergic Reaction to Certain Meats
New Alpha-Gal IgE assay is the first to specifically detect antibodies associated with a delayed-onset allergic reaction to beef, pork, and lamb, the development of which has been linked to tick bites.
Viracor-IBT Laboratories Expands Fungal Testing Services with Launch of Aspergillus PCR Panel
New testing service is the first to detect and measure deadly Invasive Pulmonary Aspergillosis
Viracor-IBT Laboratories to Present at the American College of Allergy, Asthma and Immunology’s Annual Meeting
Scientists from Viracor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year’s American College of Allergy, Asthma and Immunology’s Annual Scientific Meeting in Miami, Florida.
Viracor-IBT Laboratories Launches Comprehensive Influenza and Respiratory Virus Testing Service
New suite of tests identifies 2009 Influenza A H1N1 ("swine flu"), additional influenza subtypes and other common respiratory viruses, assisting physicians in improving patient care and ensuring appropriate antiviral use.
ViraCor Laboratories and IBT Laboratories Merging to Create Unique Specialty Diagnostics Company
Combined company draws on latest scientific research to provide the most accurate, reliable and comprehensive immunology and infectious disease tests available.
ViraCor Laboratories Launches Ultrasensitive JC Virus Test
New test will assist in the earlier diagnosis of Progressive Multifocal Leukoencephalopathy, a serious brain infection exclusively caused by JCV.
ViraCor Laboratories Launches Fastest Available Cytomegalovirus Antiviral Resistance Test
New Service Provides Comprehensive Detection of Antiviral Resistant Virus Strains in Just Three Days, Helping Physicians Treat Patients Quickly, Improve Patient Outcomes and Reduce Healthcare Costs.
ViraCor Laboratories Helps Hospitals Effectively Navigate Impending Flu Season
Unique clinical reference and research lab offers complex respiratory virus testing that improves patient care by allowing doctors to identify an infection quickly and accurately.
ViraCor Laboratories Launches Comprehensive Testing for Fungal Infections
Service begins with the introduction of two tests Platelia Aspergillus EIA and Fungitell β-D Glucan
ViraCor’s Founder and CEO Flip Short Named 2008 Ernst & Young Entrepreneur Of The Year® in the Central Midwest Region
Award Recognizes Entrepreneurial Excellence in Life Sciences Category
ViraCor Laboratories Launches New Enterovirus Test
National Clinical Reference Laboratory Provides Results in Less Than 24 Hours, Leading to Faster Diagnosis of Virus that Infects Millions of Americans Each Year
IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting
Test builds on company's suite of tests to evaluate immune function
ViraCor Laboratories Is First National Reference Laboratory To Offer Novel Respiratory Viral Testing
Newly-Cleared Respiratory Viral Panel Enables Clinicians to Improve Patient Care through Fast and Accurate Laboratory Diagnosis